Major hepatic resection for hilar cholangiocarcinoma without preoperative biliary drainage.

Hilar cholangiocarcinoma is a rare cancer in western countries but very high incidence in the northeast of Thailand. The only chance to cure is surgical resection. Preoperative biliary drainage (PBD) for improving liver function to decrease perioperative morbidity and mortality is claimed to be beneficial. To determine whether liver resection with hilar resection is a safe procedure in obstructive jaundice patients caused by hilar cholangiocarcinoma, the records of 30 consecutive patients undergoing surgery between May 1999 and May 2002 at Srinagarind hospital, Khon Kaen University, were retrospectively analyzed. Two patients died during hospitalization, an operative mortality of 6.7%. Survival was 33% at 1 year, 12% at 2 years,10% at 3 years and 6.7% at 4 years. In our experience, it is safe in most patients with obstructive jaundice due to hilar cholangiocarcinoma to perform liver resection without preoperative biliary drainage (PBD).

5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.

OBJECTIVE: To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer. MATERIAL AND METHOD: Between January 1993 and December 2000, 121 from 559 patients with advanced colorectal cancer were treated with chemotherapy. Bolus MMC (10 mg/m2) on first day, 5-FU (600 mg/m2/day) was given as a continuous infusion for 5 days, repeated every 4 weeks for 6 cycles. Toxicity and response were analyzed according to WHO criteria, and survival was analyzed according to Kaplan-Meier methodology. RESULTS: In the chemotherapy group (121 patients), 70 were males and 51 were females, the mean age was 52 years. The ratio of colon and rectal cancer was 0.57. Nearly all patients (88.89%) had tumors with moderate differentiation. Forty patients with liver metastasis showed an overall response rate of 45% (95% CI 35.4-54.6) with a CR in 3 (7.5%) and PR in 15 (37.5%). The median survival was 13.1 months. The regimen was well tolerated with 11.64% of patients experiencing WHO grade 3-4 toxicity. CONCLUSION: The present study has indicated a highly active, acceptable toxic, inexpensive regimen of old drugs to be used as an alternative to the more expensive combination including CPT-11 or oxaliplatin.